Search
Cobicistat
go.drugbank.com/drugs/DB09065ApprovedInvestigationalAlthough it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered … Increasing systemic exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and a decreased side effect profile.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesCamazepam
go.drugbank.com/drugs/DB01489ExperimentalIllicitCamazepam is a benzodiazepine which is a dimethyl carbamate ester of tamzepam, a metabolite of diazepam. … In the United States camazepam is regulated as a Schedule IV controlled substance.
Salsalate
go.drugbank.com/drugs/DB01399ApprovedInvestigationalSalsalate's mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins. … Salsalate is a nonsteroidal anti-inflammatory agent for oral administration.
Pinaverium
go.drugbank.com/drugs/DB09090ApprovedInvestigationalPinaverium is a spasmolytic agent used for functional gastrointestinal disorders. It is a quaternary ammonium compound that acts as an atypical calcium antagonist to restore normal bowel function. … Pinaverium bromide is the common ingredient in formulations, mostly as oral tablets.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesNadroparin
go.drugbank.com/drugs/DB08813ApprovedInvestigationalWithdrawnIt is derived from porcine sources and has a mean molecular size of 5000 daltons. … Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
Acellular nerve allograft
go.drugbank.com/drugs/DB30293ApprovedInvestigationalApproved by the FDA under a Biologics License Application (BLA) as an acellular nerve scaffold for the treatment of adult and pediatric patients (aged ≥1 month) with sensory, mixed, and motor peripheral
Idarucizumab
go.drugbank.com/drugs/DB09264ApprovedAs a direct acting oral anticoagulant (DOAC), one of the risks associated with the use of dabigatran includes bleeding, espeically when given to patients at increased risk (elderly, chronic kidney disease … Idarucizumab is a humanized monoclonal antibody fragment (Fab) derived from an immunoglobulin G1 isotype molecule that binds to and inactivates the oral anticoagulant dabigatran, thereby reversing its
Liposomal prostaglandin E1
go.drugbank.com/drugs/DB05391InvestigationalLiposome-encapsulated form of prostaglandin E1 (Liprostin) is known to be a potent vasodilator and platelet inhibitor as well as an anti-inflammatory and anti-thrombotic agent.
Romiplostim
go.drugbank.com/drugs/DB05332ApprovedInvestigationalEach subunit consists of an IgG1 Fc carrier domain that is covalently attached to a polypeptide sequence that contains two binding domains to interact with thrombopoietin receptor c-Mpl. … Romiplostim is a thrombopoiesis stimulating dimer Fc-peptide fusion protein (peptibody) to increase platelet production through activation of the thrombopoietin receptor.
Irofulven
go.drugbank.com/drugs/DB05786InvestigationalA novel anti-cancer compound synthesized by scientists at the University of California, San Diego more than a decade ago from toxins of the poisonous jack-o-lantern mushroom, has been granted “fast track … Phase III clinical trials involving the drug have been underway since early 2001 at sites in the U.S. and Europe.